Abstract
Introduction
The use of the purine nucleoside analog Xudarabine in allogeneic hematopoietic cell transplant (HCT) conditioning regimens has dramatically increased over the past 10 years. Fludarabine, administered as its monophosphate form over a wide dosage range of 90-250 mg/m 2 , is a key component of myeloablative, reduced-intensity, and nonmyeloablative conditioning regimens [1] . Reduced-intensity and nonmyeloablative conditioning regimens do not completely ablate the recipient's immune system, therefore resulting in a temporary state of mixed chimerism in which donor and recipient hematopoietic cells co-exist in the recipient. Chimerism is typically evaluated within various blood cell subsets [e.g., CD3
+ , natural killer (NK) and granulocytes], and higher rates of donor chimerism early after HCT have been associated with improved clinical outcomes [2] [3] [4] . Current research has focused upon identifying the optimal cell population to monitor for donor chimerism levels. Recent clinical studies suggest that higher early donor chimerism in NK cells is associated with lower relapse rates and improved progression-free survival [5] [6] [7] [8] . NK cells are an important component of innate immunity and are characterized by the expression of the CD56 antigen and a lack of expression of the T-lymphocyte marker CD3. It is critical to gain an improved understanding of predictors of NK donor chimerism in recipients of Xudarabine-based reduced-intensity and nonmyeloablative conditioning regimens.
Fludarabine must undergo active intracellular transport and metabolism to form Xudarabine triphosphate (F-ara-ATP), its active metabolite that inhibits ribonucleotide reductase and DNA polymerase and ultimately leads to cellular apoptosis in both actively dividing and resting cells [9] . Fludarabine (9--D-arabinofuranosyl-2-Xuoroadenine) is administered as the monophosphate prodrug and is rapidly dephosphorylated in plasma to Xudarabine by serum phosphatase and ecto-5Ј-nucleotidase (CD73) [9] . Intracellular uptake of Xudarabine is mediated by several nucleoside transporters, including the nitrobenzylthioinosine (NBMPR)-sensitive human equilibrative nucleoside transporter 1 (hENT1), the NBMPR-insensitive human equilibrative nucleoside transporter 2 (hENT2), and the human concentrative nucleoside transporter 3 (hCNT3) [9, 10] . Once inside the cell, Xudarabine is sequentially phosphorylated to the monophosphate (F-ara-AMP), diphosphate (F-ara-ADP), and triphosphate (F-ara-ATP) forms by deoxycytidine kinase (dCK), adenylate kinase (AK), and nucleoside diphosphate kinase (NDK), respectively [11] . F-ara-AMP can also be dephosphorylated to Xudarabine by 5Ј-nucleotidase (CN-II) and deoxynucleotidase-1 (dNT-1). The expression of these transporters and enzymes, along with their contribution to accumulation and formation of intracellular F-ara-ATP, has yet to be evaluated in NK cells.
Fludarabine administration has been shown to deplete CD4 + and CD8 + T-lymphocytes; however, there is less information regarding its pharmacological action on NK cells [12] [13] [14] . Interindividual diVerences in the ability of recipient NK cells to uptake and activate F-ara-ATP may contribute to variability in recipient NK cell survival. Inadequate suppression of recipient NK cells could lead to low donor NK cell chimerism levels, which have been associated with a higher risk of rejection and worse progression-free survival after Xudarabine-containing conditioning regimens [6] . Thus, identifying risk factors for low donor NK chimerism, such as low F-ara-ATP accumulation in NK cells, is of keen interest. We sought to determine the feasibility of evaluating F-ara-ATP accumulation in NK cells ex vivo. SpeciWcally, our goal was to isolate enough puriWed NK cells from apheresis products obtained from healthy volunteers to characterize the disposition and accumulation of F-ara-ATP in these NK cells. This allowed us to test two hypotheses: Wrst, that NK cells form F-ara-ATP intracellularly, and second, that there is a considerable interindividual variability in F-ara-ATP accumulation rates. We also evaluated the interindividual variability in the mRNA expression levels of the key transporters (hENT1, hENT2, and hCNT3) and enzymes (dCK, CN-II, and dNT-1) important in Xudarabine uptake and activation. These studies provide the Wrst evidence that characterizing the intracellular disposition of Xudarabine in human NK cells may help to identify risk factors of graft rejection or progression-free survival, and ultimately result in improved clinical outcomes.
Materials and methods

Isolation of NK cells from healthy volunteers
Prior to study procedures, written consent was obtained using forms approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center. Six healthy volunteers donated a mononuclear-enriched apheresis product. The median age of the volunteers was 32 years (range 29-51 years); Wve males and one female; four Caucasian and two Hispanic. No information regarding the past medical history or concomitant medications was available. The apheresis product was Wrst CD3-depleted using anti-CD3 magnetic microbeads to remove T-lymphocytes, and then NK cells were puriWed from the CD3-depleted fraction using anti-CD56 magnetic microbeads (Miltenyi Biotec Inc., Auburn, CA) and an AutoMACSN™ automatic magnetic cell sorter (Miltenyi Biotec Inc.) according to the manufacturer's recommendations. NK cell purities were 91.0 § 4.9% for the isolations.
Fludarabine triphosphate accumulation in NK cells
The measurement of F-ara-ATP accumulation was initiated in each puriWed NK cell population within 2 h of cell isolation. Using a procedure optimized for CD4 + and CD8 + cells [15] , 1 £ 10 6 NK cells were incubated in Xudarabine (5 M) in RPMI 1640 media (not containing phenol red) supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) antibiotic/antimycotic for 4 h at 37°C in 5% CO 2 . This concentration is in the range of the peak Xudarabine plasma concentration (3 M) after Xudarabine monophosphate administration of 30 mg/m 2 /day, the dose used in some nonmyeloablative conditioning regimens [16, 17] . Incubations were conducted in duplicate, and F-ara-ATP concentration was quantitated using the LC-MS method we have described previously [15, 18] . The units for all F-ara-ATP accumulation rates were pmol/1 £ 10 6 cells/4 h.
Gene expression analysis
Total RNA was extracted from puriWed NK cells from healthy volunteers using the gene expression protocol described previously [15] . Gene-speciWc TaqMan ® Gene Expression Assays (Applied Biosystems, Foster City, CA) were used to quantitate mRNA expression of the following key transporters: hENT1, hENT2, hCNT3, dCK, CN-II, and dNT-1 relative to an internal endogenous control -glucuronidase (GUS) on a 7900HT Fast Real-Time PCR System (Applied Biosystems) [15] . Samples were performed in triplicate and the delta-delta threshold cycle (C T ) method was used to provide an estimation of relative gene expression (arbitrary units) as described previously [15] .
Statistical analysis
Student's two-sided t test was used to evaluate diVerences between two sets of data. p values < 0.05 were considered statistically signiWcant.
Results
F-ara-ATP accumulation in NK cells
We were able to purify a suYcient number NK cells to allow for quantitation of intracellular F-ara-ATP accumulation in all six participants. Median cell yields after NK cell isolation in healthy volunteers was 1.69 £ 10 7 (range 1.09 £ 10 7 -1.91 £ 10 7 ). Substantial interindividual variability was observed in F-ara-ATP accumulation in the puriWed NK cells from healthy volunteers (Fig. 1 ). Following incubation with 5 M Xudarabine, the mean ( §SD) F-ara-ATP accumulation was 6.00 § 3.67 pmol/ 1 £ 10 6 cells/4 h ( Table 1) . F-ara-ATP accumulation rates ranged from 1.44 to 11.9 (min-max) pmol/1 £ 10 6 cells/ 4 h, which is represents an 8.3-fold variability. The replicates were within 87-100% of each other.
Gene expression in NK cells
The level of mRNA expression of the key transporters and enzymes involved in Xudarabine uptake and subsequent formation of F-ara-ATP was measured relative to an endogenous control (GUS) ( Table 1) . We observed large interindividual variability in gene expression; variability was largest in the expression of hCNT3 (47-fold), followed by hENT2 (9.3-fold), dCK (8.4-fold), hENT1 (6.3-fold), CN-II (4.4-fold), and smallest variability in dNT-1 (1.7-fold).
F-ara-ATP in NK Cells compared to T-lymphocytes Previously, we have reported the F-ara-ATP accumulation and corresponding gene expression pattern in CD4 + and CD8 + T-lymphocytes isolated from healthy volunteers and HCT recipients [15] . We compared the diVerences in F-ara-ATP accumulation and gene expression in the T-lymphocytes and NK cells isolated from healthy volunteers ( Table 1) . We were able to collect both NK cells and T-lymphocytes from three of the donors in this study; however, we were only able to obtain either NK cells or T-lymphocytes from the remaining donors. Average F-ara-ATP accumulation in NK cells was not signiWcantly diVerent from that seen in CD4 + and CD8 + T-lymphocytes. However, the interindividual variability we observed in NK cells from healthy volunteers (8.3-fold) was greater than the variability we previously reported in CD4 + and CD8 + Tlymphocytes (1.6-and 1.9-fold, respectively) [15] . We also observed diVerences in mRNA expression between NK cells and T-lymphocytes. In particular, hENT1 was signiWcantly higher in NK cells than in CD8 + cells (p < 0.005). NK cells displayed signiWcantly lower hENT2 gene expression in both CD4 + (p < 0.05) and CD8 + (p < 0.001) cells.
Discussion
Our studies are the Wrst to demonstrate that NK cells have the ability to uptake Xudarabine and activate it to F-ara-ATP, which is a novel Wnding in that there is a general impression that NK cells are resistant to Xudarabine. Thus, these reported data are a critical Wrst step to understand the eVects of Xudarabine upon NK cells. We observed considerable interindividual variability in the accumulation of F-ara-ATP in NK cells as well as in the mRNA expression of the key genes involved in Xudarabine uptake and activation. The overall level of F-ara-ATP accumulation in NK cells is similar to what we observed previously in CD4 + and CD8 + T-lymphocytes in healthy volunteers [15] ; however, the degree of variability appears larger in NK cells. Our method of measuring F-ara-ATP accumulation has the potential to be used to evaluate interindividual variability in patients receiving Xudarabine-containing conditioning regimens prior to receiving allogeneic HCT, and could serve as a possible predictor of subsequent donor NK chimerism.
Currently, there are few studies examining the pharmacokinetic and pharmacodynamic eVects of Xudarabine upon NK cells, and seemingly contradictory results have been reported. Early in vitro and animal studies suggest that NK cells do not require proliferation for their activity and that Xudarabine exposure actually enhanced NK cell activity [12, 13] . However, a recent study in 34 chronic lymphocytic leukemia patients suggests that the initial administration of Xudarabine (doses not described) led to a decrease in the number of CD56
+ -expressing cells after 3 months [14] . Further, Xudarabine administration from 3 to 6 months led to a slight increase in NK counts; however, these counts still did not return to the baseline levels observed prior to Xudarabine administration [14] . In our study, we have shown that puriWed human NK cells have the ability to uptake Xudarabine and form F-ara-ATP, its active cytotoxic metabolite. The average F-ara-ATP accumulation in NK cells was comparable to that seen in CD4 + and CD8 + T-lymphocytes (Table 1 ). This level of T-lymphocyte F-ara-ATP accumulation was suYcient to lead to loss of cell viability after 24-h incubation with Xudarabine [15] . Future studies should address if F-ara-ATP accumulation rates are associated with apoptosis in human NK cells. Average F-ara-ATP accumulations in healthy volunteers were not signiWcantly diVerent between NK cells and CD4 + and CD8 + T-lymphocytes, which were reported previously (Table 1 ) [15] . However, we did observe substantially greater interindividual variability in F-ara-ATP accumulation in NK cells compared to T-lymphocytes [15] . A limitation is that only demographic data (i.e., no information regarding past medical history or concomitant medications) was available on these healthy volunteers. In our previous report, we also demonstrated that variability is greater in T-lymphocytes isolated from HCT patients than from healthy volunteers [15] . If this trend is similar in NK cells, we would expect even larger interindividual variability in F-ara-ATP accumulation in NK cells from HCT patients. Large interindividual diVerences in F-ara-ATP accumulation in recipient NK cells may lead to variable killing of those cells after Xudarabine administration and aVect donor NK cell chimerism levels. Higher donor chimerism of NK cells at day-14 and day-28 post-nonmyeloablative HCT, more so than that of CD4 + or CD8 + T-lymphocytes, has been associated with lower rejection rates and improved progression-free survival [5, 6] . Therefore, overall recipient and donor NK cell counts during the Wrst 4-5 weeks after Xudarabine treatment may be clinically important; and insuYcient suppression of recipient NK cells prior to HCT may be a critical factor leading to low donor chimerism early post-transplant. Successful nonmyeloablative conditioning with Xudarabine may correlate with reduced functionality and survival of recipient NK cells, which would in turn be associated with improved progression-free survival. Therefore, it may be desirable to quantitate the recipient's NK cell F-ara-ATP accumulation prior to conditioning, and adjust Xudarabine doses accordingly to maximize the suppression of recipient NK cells such that optimal early donor NK chimerism can be achieved. Ideally, future studies would evaluate the association between F-ara-ATP accumulation in NK cells and clinical response. However, a major diYculty towards such studies is obtaining suYcient number of NK cells to measure F-ara-ATP accumulation from HCT recipients. Even with our highly sensitive analytical method for F-ara-ATP quantitation, a relatively large number of NK cells (i.e., 1.25 £ 10 5 cells/incubate) must be obtained from HCT recipients to measure F-ara-ATP accumulation ex vivo. We were able to isolate suYcient quantities from NK cells from apheresis products, but this method may not be practical for HCT recipients prior to Xudarabine administration. The number of NK cells isolated from apheresis products was almost twofold less than the number of CD4 + or CD8 + T-lymphocytes isolated from the same amount of apheresis product [15] . Also in our previous study, we compared F-ara-ATP accumulation in T-lymphocytes isolated from apheresis products donated by healthy volunteers and peripheral blood draws (60 mL) donated by HCT patients. Our median cell yields after isolation of CD4 + and CD8 + Tlymphocytes were almost a log of magnitude less in HCT patients compared to healthy volunteers [15] . Thus, it is very likely that the number of NK cells one can obtain from patients awaiting HCT will not be suYcient to quantitate ex vivo F-ara-ATP formation. Therefore, more sensitive methods (e.g., immunoassay) requiring less cell numbers are needed for future studies investigating the relationship between F-ara-ATP accumulation in NK cells and clinical response. The identiWcation of surrogates for F-ara-ATP accumulation rate may also be of beneWt in determining whether the eYcacy (e.g., immunosuppression) and toxicity of Xudarabine can be predicted in HCT recipients.
We observed signiWcant interindividual variability in the gene expression of the transporters and enzymes involved in Xudarabine uptake and subsequent activation to F-ara-ATP. It would be interesting to see whether expression levels of these genes are related to the ability of NK cells to form F-ara-ATP. Unfortunately, the number of healthy volunteers in our study is too small to allow for meaningful statistical analyses examining such a relationship. In a previous study, we did not Wnd an association between F-ara-ATP accumulation and gene expression in CD4 + and CD8 + T-lymphocytes isolated from HCT patients [15] . Other studies have also found that mRNA expression is not a good marker for activity of the enzymes and transporters relevant in Xudarabine triphosphate uptake and activation [10, 19, 20] . As mRNA expression levels do not always correlate with protein expression and activity, additional studies directly evaluating protein expression and activities of the relevant transporters and enzymes may be useful in identifying potential surrogate markers of F-ara-ATP accumulation in NK cells.
In conclusion, we demonstrated that NK cells form F-ara-ATP and have observed signiWcant interindividual variability in F-ara-ATP accumulation in NK cells isolated from healthy volunteers. Further work is needed to directly evaluate the pharmacodynamic relationships between F-ara-ATP accumulation in NK cells with apoptosis ex vivo and clinical outcomes in vivo. Variable Xudarabine uptake and activation in recipient NK cells may lead to variable clinical outcomes in HCT patients, particularly aVecting the levels of donor NK cell chimerism, the rate of engraftment, and progression-free survival. Understanding interindividual variability in F-ara-ATP accumulation in NK cells may help to optimize Xudarabine-containing conditioning regimens prior to HCT and enhance the therapeutic outcomes for these patients.
